Inventiva And Hepalys Pharma, Inc. Announce Exclusive Licensing Agreement To Develop And Commercialize Lanifibranor In Japan And South Korea
Portfolio Pulse from Benzinga Newsdesk
Inventiva (NASDAQ:IVA) and Hepalys Pharma, Inc. have entered into an exclusive licensing agreement to develop and commercialize Inventiva's drug candidate lanifibranor in Japan and South Korea. Inventiva will receive a $10 million upfront payment and is eligible to receive up to $231 million in milestone payments. Inventiva has a 30% ownership in Hepalys Pharma and the option to acquire all outstanding shares of Hepalys Pharma.
September 20, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inventiva's partnership with Hepalys Pharma for the development and commercialization of lanifibranor in Japan and South Korea could potentially increase Inventiva's revenues through upfront and milestone payments.
The licensing agreement with Hepalys Pharma provides Inventiva with an upfront payment of $10 million and potential milestone payments of up to $231 million. This could significantly increase Inventiva's revenues if the development and commercialization of lanifibranor are successful. Furthermore, Inventiva's 30% ownership in Hepalys Pharma and the option to acquire all outstanding shares of Hepalys Pharma could provide additional financial benefits.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100